Cannabinoids in Alzheimer’s disease: animal–human evidence and clinical pharmacology challenges
Abstract Cannabinoids have emerged as potential modulators of pathological processes in Alzheimer’s disease (AD), including neuroinflammation, synaptic dysfunction, and protein…